bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia
bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its investigational LentiGlobin™ gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype.
LentiGlobin was previously granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA in July 2018, potentially reducing the EMA’s active review time of the MAA from 210 days to 150 days.
“People living with transfusion-dependent β-thalassemia require frequent blood transfusions that are life-saving but may lead to complications, including organ failure due to iron overload,” said David Davidson, M.D., chief medical officer, bluebird bio. “The acceptance of our marketing authorization application for LentiGlobin is a milestone that advances us toward our goal of providing to patients the first one-time gene therapy that addresses the underlying genetic cause of TDT. We share this important milestone with the patients, families and healthcare providers who made it possible through their participation in our pioneering clinical studies of LentiGlobin.”
The MAA for LentiGlobin is supported by data from the completed Phase 1/2 Northstar (HGB-204) study and the ongoing Phase 1/2 HGB-205 study as well as available data from the Phase 3 Northstar-2 (HGB-207) study and the long-term follow-up study LTF-303.
About Transfusion-Dependent β-Thalassemia
TDT is an inherited blood disorder caused by a mutation in the β-globin gene, which causes ineffective red blood cell production leading to severe anemia. Supportive care for people with TDT consists of a lifelong regimen of chronic blood transfusions to enable survival and suppress symptoms of the disease, and iron chelation therapy to manage iron overload that results from the transfusions.
Despite the availability of supportive care, many people with TDT experience serious complications and organ damage due to underlying disease and iron overload. By eliminating or reducing the need for blood transfusions, the long-term complications associated with TDT may be reduced.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been successfully used to treat TDT and is currently the only available option with the potential to correct the genetic deficiency in TDT. Complications of allo-HSCT include a risk of treatment-related mortality, graft failure, graft-versus-host disease (GvHD) and opportunistic infections, particularly in patients who undergo non-sibling matched allo-HSCT.
LentiGlobin is a one-time gene therapy being studied as a potential treatment to address the underlying genetic cause of TDT, which could eliminate or reduce the need for blood transfusions.
bluebird bio’s clinical development program for LentiGlobin includes ongoing studies around the world with sites in Australia, Germany, Greece, France, Italy, Thailand, the United Kingdom and the United States. For more information visit: www.northstarclinicalstudies.com or clinicaltrials.gov using identifier NCT01745120.
In addition, bluebird is conducting a long-term safety and efficacy follow-up study (LTF-303) for people who have participated in bluebird bio-sponsored clinical studies of LentiGlobin for TDT and sickle cell disease.
The EMA previously granted Priority Medicines (PRIME) eligibility and Orphan Medicinal Product designation to LentiGlobin for the treatment of TDT. LentiGlobin is also part of the EMA’s Adaptive Pathways pilot program, which is part of the EMA’s effort to improve timely access for patients to new medicines.
The U.S. Food and Drug Administration (FDA) also granted LentiGlobin Orphan Drug status and Breakthrough Therapy designation for the treatment of TDT.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built a pipeline with broad potential application in severe genetic diseases and cancer.
bluebird bio's gene therapy clinical programs include investigational treatments for cerebral adrenoleukodystrophy, transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease.
bluebird bio's oncology pipeline is built upon the company's lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. The company’s lead oncology programs are anti-BCMA CAR T programs partnered with Celgene.
bluebird bio’s discovery research programs include utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts; Seattle, Washington; Durham, North Carolina and Zug, Switzerland.
LentiGlobin is a trademark of bluebird bio, Inc.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s views with respect to the potential for its LentiGlobin product candidate to treat transfusion-dependent ß-thalassemia, and the Company’s expectations regarding the review, potential regulatory approval and potential commercial launch of its LentiGlobin product candidate in the United States and Europe. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials of LentiGlobin will not continue or be repeated in our ongoing or planned clinical trials of LentiGlobin, the risks that the changes we have made in the LentiGlobin manufacturing will not result in improved patient outcomes, risks that the current or planned clinical trials of LentiGlobin will be insufficient to support future regulatory submissions or to support marketing approval in the US and EU, and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
C.H. Robinson Acquires Dema Service S.p.A. to Expand Global Presence23.5.2019 14:00:00 EEST | Tiedote
C.H. Robinson (NASDAQ: CHRW) continues to expand its global footprint with its announcement of the acquisition of Dema Service S.p.A. (Dema Service) on May 22, 2019. Dema Service is a leading provider of European road transportation based in Italy. “The acquisition of Dema Service is an exciting milestone for C.H. Robinson and will strengthen our existing footprint in Italy, one of the largest road transportation markets in Europe,” said Jeroen Eijsink, President of Europe for C.H. Robinson. “We are eager to work with Dema Service’s customers to offer our full suite of logistics services to help improve their supply chains.” This is the second European acquisition for C.H. Robinson in 2019. The company recently acquired the freight forwarding group Space Cargo, which expanded C.H. Robinson’s presence in Spain and Columbia. Dema Service is a privately-owned logistics company providing road transportation services across Europe. Headquartered in Pescara, Italy, Dema Service has approxima
Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform23.5.2019 13:30:00 EEST | Tiedote
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/ FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire) Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market. LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manua
Network of 1,500 Stroke-Ready Clinics across Europe23.5.2019 13:00:00 EEST | Tiedote
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved. The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies. “Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Ange
Dawex Raises €5 Million to Accelerate the Development of the Data Economy23.5.2019 09:45:00 EEST | Tiedote
Dawex, a leading data exchange technology company and the operator of the largest data marketplace, today announced a new round of funding of €5 million with Amadeus (AMS.MC), Itochu Corporation (ITOCY), Bouygues Construction (BOUY.PA) and a French web entrepreneur entering Dawex’s capital, also joined by the historical investor Caisse des Dépôts (via its Banque des Territoires). Total funds raised from inception tops €12 million, including the recent €2.5M grant from Horizon 2020, the biggest European Union Research & Innovation program. Dawex co-founders Fabrice Tocco and Laurent Lafaye remain majority shareholders, retaining full control over the company’s strategy and operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005927/en/ With the rise of Artificial Intelligence, Internet of Things, and the emergence of Smart Cities, among other disruptive trends like the autonomous cars, huge quantities of valuable
TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment23.5.2019 09:00:00 EEST | Tiedote
COMPLETION OF SERIES B FUNDRAISE TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market. BOARD UPDA
Buy and Sell Globally: 2019 Yiwu Imported Commodities Fair Opens in “World’s Capital of Small Commodities”23.5.2019 07:46:00 EEST | Tiedote
On May 23-26, China Yiwu Imported Commodities Fair 2019 opened at Yiwu International Expo Center in Eastern China’s Yiwu city – the world’s capital of small commodities. The Fair of this year provides 2,012 standard booths in five halls, namely Asia I, Asia II, Europe, America-Australia-Africa & Cross-border Trade & Zhenjiang-International Sister Cities Exchange, and Imported Sweets and Wines, with an exhibition area of over 50,000m2 . Among the nearly 1,000 exhibitors from 85 countries and regions, 170 are from 40 countries and regions along the “Belt and Road” to exhibit daily necessities, home supplies, handicrafts, foods and drinks. Echoing China International Import Expo (CIIE), a special area is reserved for over 20 CIIE companies to exhibit their quality products including Bosch Group (Germany), skin care brand Rilastil (Italy), and Alligga (Canada) specializing in health products for a complete and balanced lifestyle. In addition, a special area for international sister cities
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme